Echo Therapeutics Announces CEO, President and Chairman, Dr. Patrick Mooney is Taking Leave of Absense

Echo Therapeutics, Inc.

, a company developing its non-invasive Symphony® CGM System as a needle-free, wireless continuous glucose monitoring system, today announced that its Chief Executive Officer, President and Chairman of the Board, Dr. Patrick Mooney, is taking an immediate leave of absence.  Robert Doman, a member of Echo's Board of Directors, will serve as Executive Chairman and Interim Chief Executive Officer.  Mr. Doman has over 30 years of executive level, international and domestic management, business development, sales and marketing, product development and strategic planning experience with specific concentrations in medical devices and pharmaceuticals.  Most recently, Mr. Doman served as President and Chief Executive Officer of publicly-traded DUSA Pharmaceuticals, Inc., which was successfully sold to Sun Pharmaceuticals in a $230 million transaction in 2012.  Effective immediately, William Grieco, Chairman of the Company's Nominating and Corporate Governance Committee and a member of Echo's Board since February 2011, has been appointed Lead Independent Director of the Board.